CSL Behring and Ferring Pharmaceuticals have announced additional information about a recent recall of lots of Stimate® that was originally issued July 21, 2020.

Stimate® Nasal Spray is owned and manufactured by Ferring Pharmaceuticals Inc., and is distributed and sold in the United States by CSL Behring. After further collaboration with the FDA, Ferring is now extending the recall to the consumer level. This product is being recalled due to superpotency or amounts of desmopressin higher than specified. These out of specification results were identified during routine testing.

The risks associated with higher than specified amounts of desmopressin relate to abnormally low level of sodium in the blood which could potentially lead to seizure, coma, and death. To date, Ferring has not received an increase in adverse event reports due to increased concentrations from users of the nasal spray. A single non-fatal adverse event potentially associated with this issue was reported in the US during the timeframe that the affected product was distributed.

Ferring is recalling all batches of Stimate® Nasal Spray. The table below provides detail for all impacted batches of Stimate® that were shipped to CSL Behring beginning on December 15, 2017.

This recall is to be conducted to the consumer level and is being conducted with the knowledge of the FDA.  The following batches have been affected:


Patients in possession of any vials from any of these lots should contact your Authorized Distributor’s Customer Service to facilitate a return to them. If a healthcare provider or patient has any questions they are encouraged to call CSL’s Medical Information line at 1-800-504-5434 or email to MedinfoNA@cslbehring.com.

 Read the full product and recall details

Read the joint HFA/NHF Letter sent to CSL Behring & Ferring